JPH0570360A - Androgenic hormone-resistant agent - Google Patents
Androgenic hormone-resistant agentInfo
- Publication number
- JPH0570360A JPH0570360A JP3258569A JP25856991A JPH0570360A JP H0570360 A JPH0570360 A JP H0570360A JP 3258569 A JP3258569 A JP 3258569A JP 25856991 A JP25856991 A JP 25856991A JP H0570360 A JPH0570360 A JP H0570360A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- galenicals
- hormone
- active ingredient
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract description 6
- 239000003098 androgen Substances 0.000 title abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 91
- 241000196324 Embryophyta Species 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000000051 antiandrogen Substances 0.000 claims description 10
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 7
- 241000847801 Simaba cedron Species 0.000 claims description 7
- 240000001592 Amaranthus caudatus Species 0.000 claims description 6
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims description 6
- 244000217406 Crataegus pubescens Species 0.000 claims description 6
- 235000009692 Crataegus pubescens Nutrition 0.000 claims description 6
- 235000003130 Arctium lappa Nutrition 0.000 claims description 5
- 235000008078 Arctium minus Nutrition 0.000 claims description 5
- 235000003880 Calendula Nutrition 0.000 claims description 5
- 240000001432 Calendula officinalis Species 0.000 claims description 5
- 244000294263 Arctium minus Species 0.000 claims description 4
- 241001648652 Croton ovalifolius Species 0.000 claims description 4
- 244000023431 Proboscidea parviflora Species 0.000 claims description 4
- 235000019096 Proboscidea parviflora Nutrition 0.000 claims description 4
- 235000019512 sardine Nutrition 0.000 claims description 2
- 235000011201 Ginkgo Nutrition 0.000 claims 2
- 244000194101 Ginkgo biloba Species 0.000 claims 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims 2
- 241000555825 Clupeidae Species 0.000 claims 1
- 235000013490 limbo Nutrition 0.000 claims 1
- 210000003456 pulmonary alveoli Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 210000002374 sebum Anatomy 0.000 abstract description 7
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 6
- 206010000496 acne Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 229940088597 hormone Drugs 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 201000004384 Alopecia Diseases 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 241000931332 Cymbopogon Species 0.000 abstract description 3
- FEPOUSPSESUQPD-UHFFFAOYSA-N Cymbopogon Natural products C1CC2(C)C(C)C(=O)CCC2C2(C)C1C1(C)CCC3(C)CCC(C)C(C)C3C1(C)CC2 FEPOUSPSESUQPD-UHFFFAOYSA-N 0.000 abstract description 3
- 208000001840 Dandruff Diseases 0.000 abstract description 3
- 241001494501 Prosopis <angiosperm> Species 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 3
- 230000003054 hormonal effect Effects 0.000 abstract description 3
- 240000008554 Aloysia triphylla Species 0.000 abstract description 2
- 235000013668 Aloysia triphylla Nutrition 0.000 abstract description 2
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 240000000058 Argemone mexicana Species 0.000 abstract description 2
- 235000006770 Malva sylvestris Nutrition 0.000 abstract description 2
- 241000326840 Minthostachys setosa Species 0.000 abstract description 2
- AVFIYMSJDDGDBQ-UHFFFAOYSA-N Parthenium Chemical compound C1C=C(CCC(C)=O)C(C)CC2OC(=O)C(=C)C21 AVFIYMSJDDGDBQ-UHFFFAOYSA-N 0.000 abstract description 2
- 241001495454 Parthenium Species 0.000 abstract description 2
- 244000038594 Phyllanthus urinaria Species 0.000 abstract description 2
- 244000302909 Piper aduncum Species 0.000 abstract description 2
- 235000016761 Piper aduncum Nutrition 0.000 abstract description 2
- 241000694414 Sapindus saponaria Species 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 241000197528 Bauhinia aculeata Species 0.000 abstract 1
- 240000009005 Calendula arvensis Species 0.000 abstract 1
- 235000007864 Calendula arvensis Nutrition 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 241000207925 Leonurus Species 0.000 abstract 1
- 240000002129 Malva sylvestris Species 0.000 abstract 1
- 244000242564 Osmanthus fragrans Species 0.000 abstract 1
- 235000019083 Osmanthus fragrans Nutrition 0.000 abstract 1
- 244000184734 Pyrus japonica Species 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102000001307 androgen receptors Human genes 0.000 description 9
- 108010080146 androgen receptors Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 8
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- -1 oxendron Chemical compound 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002280 anti-androgenic effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000005814 piedra Diseases 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 201000009862 superficial mycosis Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241001552592 Hypochaeris sessiliflora Species 0.000 description 2
- 240000000982 Malva neglecta Species 0.000 description 2
- 235000000060 Malva neglecta Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000003236 psychic effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000011684 sodium molybdate Substances 0.000 description 2
- 235000015393 sodium molybdate Nutrition 0.000 description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 1
- 206010004385 Benign neoplasm of prostate Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000723343 Cichorium Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241000091577 Mexicana Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241001237767 Phalanta Species 0.000 description 1
- 240000009222 Prosopis chilensis Species 0.000 description 1
- 241000580938 Sapindus Species 0.000 description 1
- 241001125048 Sardina Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000015157 algarrobo Nutrition 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 229940098366 cola extract Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、植物抽出物を利用した
抗男性ホルモン剤に関する。TECHNICAL FIELD The present invention relates to an antiandrogen agent using a plant extract.
【0002】[0002]
【従来の技術】皮膚において、皮脂は水分の蒸散を防
ぎ、皮膚のなめらかさを保つために必要であり、さら
に、体内への異物の混入を防ぐという役割をもつ。ま
た、頭皮においても毛髪の美しさを保つために、皮脂が
必要である。2. Description of the Related Art In the skin, sebum is necessary for preventing the evaporation of water and keeping the skin smooth, and also has the role of preventing foreign substances from entering the body. Also, sebum is necessary for the scalp to maintain the beauty of hair.
【0003】しかしその分泌が過剰になると、べたつい
て汚れやすく、病原菌が繁殖しやすくなる。脂漏、ニキ
ビ、頭皮におけるふけやかゆみ、男性型脱毛症の原因は
すべて皮脂分泌亢進によるものである。However, if the secretion is excessive, it becomes sticky and easily soiled, and pathogenic bacteria are easily propagated. Seborrhea, acne, dandruff and itching on the scalp, and male pattern baldness are all due to increased sebum secretion.
【0004】皮脂の分泌亢進は男性ホルモンの活性過剰
により起こると考えられている。この他にも従来から、
男性ホルモンが関与している疾患として、多毛症、ざ
瘡、脂漏、前立腺肥大症、前立腺腫瘍等が知られてお
り、いずれも男性ホルモンの活性過剰が原因と考えられ
ている。特に、テストステロンの代謝物である5α−ジ
ヒドロテストステロン(DHT)が疾患の原因であるこ
とが、種々の研究の結果明らかにされている。これらの
疾患の治療には種々の抗男性ホルモン剤が用いられてお
り、その作用は、例えば、標的器官においてテストステ
ロンを生物活性の高いDHTに還元させる5α−リダク
ターゼの活性を阻害する、或は、生成したDHTと標的
細胞内の受容体との結合を阻害することによるものであ
る。[0004] It is considered that the increase in sebum secretion is caused by the hyperactivity of male hormones. In addition to this, from the past,
Hypertension, acne, seborrhea, benign prostatic hyperplasia, prostate tumor and the like are known as diseases in which male hormones are involved, and all are considered to be caused by excessive activity of male hormones. In particular, various studies have revealed that 5α-dihydrotestosterone (DHT), which is a metabolite of testosterone, causes disease. Various antiandrogens have been used for the treatment of these diseases, and their action inhibits, for example, the activity of 5α-reductase that reduces testosterone to highly bioactive DHT in the target organ, or This is due to inhibition of the binding between the produced DHT and the receptor in the target cell.
【0005】しかしながら、これらの抗男性ホルモン
剤、例えばシプロテロンアセテート、オキセンドロン、
酢酸クロルマジノン等はステロイドホルモン誘導体であ
るため効果は認められるが、ホルモン作用等の好ましく
ない副作用を持ち安全性に問題があるために、特に、皮
脂分泌抑制、ニキビの予防と治療、頭皮におけるふけ、
かゆみや脱毛の防止に有効な化粧料などのように長期に
わたって使用するものに配合することは適さない。However, these antiandrogens, such as cyproterone acetate, oxendron,
Chlormadinone acetate, etc. is a steroid hormone derivative, so its effect is recognized, but because of its unfavorable side effects such as hormone action and safety problems, in particular, sebum secretion suppression, prevention and treatment of acne, dandruff on the scalp,
It is not suitable for blending into long-term products such as cosmetics which are effective in preventing itching and hair loss.
【0006】[0006]
【発明が解決しようとする課題】本発明は、ホルモン様
作用を持たず、安全性の高い抗男性ホルモン剤を提供す
るものである。DISCLOSURE OF THE INVENTION The present invention provides a highly safe anti-androgen agent having no hormone-like action.
【0007】[0007]
【課題を解決するための手段】本発明の抗男性ホルモン
剤は、以下の(1)〜(22)の植物から選ずれる少な
くとも一種の抽出エキスを有効成分とすることを特徴と
する。このうち、(1)〜(8)は和漢生薬であり、主
としてアンドロゲン受容体結合阻害作用を有する。ま
た、(9)〜(22)はペルー産生薬であり、5α−リ
ダクターゼ阻害作用およびアンドロゲン受容体結合阻害
作用を有する。The anti-androgen agent of the present invention is characterized in that it contains at least one extract selected from the following plants (1) to (22) as an active ingredient. Among these, (1) to (8) are Japanese and Chinese herbs, which mainly have an inhibitory effect on androgen receptor binding. Further, (9) to (22) are Peru-producing drugs, which have a 5α-reductase inhibitory action and an androgen receptor binding inhibitory action.
【0008】(1) ウスベニアオイ (2) ヤクモソウ (3) ゴボウシ (4) キンセンカ (5) クサノオウ (6) サイカチ (7) サンシシ (8) キンモクセイ(1) Common mallow (2) Yakusou (3) Burdock (4) Calendula (5) Magnolia (6) Psychic (7) Sanshishi (8) Antler
【0009】(9) セドロン(Cedron)(学
名:リピア・トリフィラ;Lippia triphy
lla) (10) イエルバ・ルイサ(Hierba Luis
a)(学名:シンボポゴン・シトラトゥルス;Cymb
opogon citratrus)(9) Cedron (scientific name: Lipia triphyra; Lippia triphy
lla) (10) Hierba Luis
a) (Scientific name: Cymbopogon citrus); Cymb
opogon citrus)
【0010】(11) アチコリア(Achicori
a)(学名:チコリウム・インティブス;Chicho
rium intybus) (12) マチコ(Matico)(学名:ピパー・エ
ロンガトウム;Piper elongatum)(11) Achicoria
a) (Scientific name: Cichorium intibus; Chicho
riam intybus) (12) Matico (scientific name: Piper elongatum)
【0011】(13) カルド・サント(Cardo
Santo)(学名:アルゲモネ・メキシカナ;Arg
emone mexicana) (14) オルティガ・ネグラ(Ortiga neg
ra)(学名:Urens Jacq.)(13) Cardo Santo
Santo) (Scientific name: Argemone Mexicana; Arg
(Emone mexicana) (14) Ortiga negra
ra) (Scientific name: Urens Jacq.)
【0012】(15) チャンカピエドラ(Chanc
apiedra)(学名:ファランタス・ニルリ;Ph
yllanthus niruri) (16) ムナ(Muna)(学名:ミントスタキス・
セトサ;Minthostachys setosa)(15) Chanka Piedra
apiedra) (scientific name: Phalantas niluri; Ph
yllanthus niruri (16) Muna (scientific name: mintstachys
Setosa; Minthostachys setosa)
【0013】(17) アズナック−コラ(Asnac
−ccora)(学名:Atachys bogote
nsis) (18) コロケ(Choloque)(学名:サピン
ドゥス・サポナリア;Sapindus sapona
ria)(17) Asnac-Kora (Asnac
-Ccora) (scientific name: Attachys bogote
(18) Coloque (scientific name: Sapindus saponaria; Sapindus sapona)
ria)
【0014】(19) ウナ・デ・ガト(Una de
gato)(学名:ボウヒニア・アクレータ;Bau
hinia aculeata) (20) キウィチャ(Kiwicha)(学名:アマ
ラントゥス;Amarantus sp.)(19) Una de Gato
gato) (Scientific name: Bowhinia Actor; Bau
(20) Kiwicha (scientific name: Amarantus sp.)
【0015】(21) アルガロボ(Algarrob
o)(学名:プロソピス・シレンシス;Prosopi
s cilensis) (22) マンザニラ(Manzanilla)(学
名:クリサンテマム・パルテニウム;Chrysant
hemum parthenium)(21) Algarrob
o) (Scientific name: Prosopis sirensis; Prosopi
s cilensis (22) Manzanilla (scientific name: Chrysanthemum parthenium; Chrysant)
hemum parthenium)
【0016】[0016]
【発明の実施態様】本発明の抽出エキスは、植物体を乾
燥あるいはそのまま粉砕したものを溶媒抽出することに
より得られ、この抽出液をそのまま用いても、あるいは
希釈液としたり、濃縮エキスとしてもよく、また、凍結
乾燥などにより乾燥粉末物としたり、ペースト状に調製
してもよい。BEST MODE FOR CARRYING OUT THE INVENTION The extract of the present invention is obtained by subjecting a plant to a dry or crushed product and subjecting it to solvent extraction. The extract may be used as it is, or may be used as a diluent or as a concentrated extract. Alternatively, it may be made into a dry powder by freeze-drying or the like, or may be prepared as a paste.
【0017】溶媒抽出は、メタノール、エタノール、ブ
タノール等のアルコール、ヘキサン、ヘプタン、シクロ
ヘキサン等の脂肪族炭化水素、酢酸エチル等のエステ
ル、アセトン等のケトンまたは水を単独または混合して
用いることにより実施でき、通常、3〜70℃程度の温
度で抽出処理する。Solvent extraction is carried out by using alcohols such as methanol, ethanol and butanol, aliphatic hydrocarbons such as hexane, heptane and cyclohexane, esters such as ethyl acetate, ketones such as acetone or water alone or in combination. It is possible, and the extraction treatment is usually performed at a temperature of about 3 to 70 ° C.
【0018】本発明の抗男性ホルモン剤は、男性ホルモ
ンの活性過剰が原因と考えられている種々の疾患、例え
ば、男性型脱毛症、ざ瘡、前立腺肥大症等の治療に安全
かつ効果的に用いることができ、また、にきび予防や頭
髪用等の化粧料として使用することもできる。The anti-androgen agent of the present invention is safe and effective for the treatment of various diseases which are considered to be caused by excessive activity of androgen, such as androgenetic alopecia, acne, benign prostatic hyperplasia and the like. It can also be used as a cosmetic for preventing acne and for hair.
【0019】本発明の抗男性ホルモン剤の剤型としては
錠剤、カプセル剤、散剤、内服液、細粒剤、顆粒剤等の
内服剤になすことができ、また、リニメント剤、スプレ
ー剤、ローション剤、軟膏剤等の外皮用剤になすことも
できる。The anti-androgen of the present invention can be used in the form of tablets, capsules, powders, oral liquids, fine granules, granules, etc., and also liniments, sprays, lotions. It can also be used as an external skin agent such as an agent or an ointment.
【0020】[0020]
【発明の効果】本発明の抗男性ホルモン剤は、ホルモン
様作用をもたず、しかも高い抗男性ホルモン活性を有
し、男性ホルモンが関与する種々の疾患の予防および治
療に有用であり、医薬、化粧料など広範な用途に用いら
れる。INDUSTRIAL APPLICABILITY The anti-androgen agent of the present invention has no hormone-like action, has a high anti-androgen activity, and is useful for the prevention and treatment of various androgen-related diseases. It is used in a wide range of applications such as cosmetics.
【0021】[0021]
実施例1 乾燥ウスベニアオイ細断物10g、乾燥ヤクモソウ細断
物10g、乾燥ゴボウシ細断物20g、乾燥キンセンカ
細断物10g、乾燥クサノオウ細断物10g、乾燥サイ
カチ細断物10g、乾燥サンシシ細断物20g、乾燥キ
ンモクセイ細断物10gに各々10倍量(w/v)の3
0%(v/v)エタノール水溶液を加え50℃の水浴中
で2時間抽出した。次にろ過し、エタノールを除去した
後凍結乾燥して下記の通りの抽出エキスをそれぞれ得
た。Example 1 10 g of dried shredded mallow, 10 g of dried yamwort shredded, 20 g of dried burdock shredded, 10 g of dried calendula shredded, 10 g of dried shredded shredded, 10 g of dried shredded shredded, dried shredded shredded 20g, dried ginseng shredded matter 10g, 10 times amount (w / v) of 3
A 0% (v / v) ethanol aqueous solution was added, and the mixture was extracted for 2 hours in a water bath at 50 ° C. Next, the mixture was filtered, ethanol was removed, and then freeze-dried to obtain the following extract extracts.
【0022】 ウスベニアオイ抽出エキス 1.008g ヤクモソウ抽出エキス 0.519g ゴボウシ抽出エキス 1.699g キンセンカ抽出エキス 2.641g クサノオウ抽出エキス 2.158g サイカチ抽出エキス 2.149g サンシシ抽出エキス 2.436g キンモクセイ抽出エキス 2.518gScutellaria asiatica extract 1.008 g Yakusou extract 0.519 g Burdock extract 1.699 g Calendula extract 2.641 g Kanoshino extract 2.158 g Psychic extract 2.149 g Sardine extract 2.436 g Ginseng extract 2.518 g
【0023】試験例1:アンドロゲン受容体とDHTと
の結合阻害効果 本試験はTakayasu等の方法(J.Steroi
d Biochem.Vol.19 pll41−11
46,1983)に準拠して行なった。Test Example 1: Effect of inhibiting binding between androgen receptor and DHT This test is carried out by the method of Takayasu et al. (J. Steroy).
d Biochem. Vol. 19 pll41-11
46, 1983).
【0024】(1)アンドロゲン受容体溶液の調製 wistar系雄性ラット(12週令)を去勢し、24
時間後に前立腺を摘出し、50mMトリス塩酸緩衝液
(pH7.4)、1.5mMエチレンジアミン四酢酸、
1mMジチオスレイトール、10mMモリブデン酸ナト
リウムおよび10%(w/v)グリセロールを含有する
4倍量(w/v)の溶液でホモジナイズした後、700
×g、4℃で10分間遠心して得られた上清を採取し
た。この上清を更に105000×g、4℃で1時間遠
心して上清を得、この上清をアンドロゲン受容体溶液と
した。(1) Preparation of Androgen Receptor Solution Wistar male rats (12 weeks old) were castrated to give 24
After a lapse of time, the prostate was removed, and 50 mM Tris-HCl buffer (pH 7.4), 1.5 mM ethylenediaminetetraacetic acid,
After homogenizing with a 4-fold (w / v) solution containing 1 mM dithiothreitol, 10 mM sodium molybdate and 10% (w / v) glycerol, 700
The resulting supernatant was collected by centrifugation at × g for 10 minutes at 4 ° C. This supernatant was further centrifuged at 105,000 × g at 4 ° C. for 1 hour to obtain a supernatant, which was used as an androgen receptor solution.
【0025】(2) アンドロゲン受容体結合阻害活性
の測定 1nM[3H]DHT(100Ci/mmol)と40
0nM−DHTと上記(1)項による受容体溶液と種々
の濃度の検体試料との混合溶液(全量250μl)を4
℃で16時間インキュベートした後、5%(w/v)活
性炭および0.5%(w/v)デキストラン(分子量6
0000〜90000)を含有する溶液250μlを添
加して4℃で10分間遠心して上清を得た。この上清2
00μlを取り液体シンチレーションカクテルと混和し
た後、液体シンチレーションカウンターを用いて受容体
への[3H]DHTの特異的結合量を測定し、次式数1
より阻害率を求める。(2) Measurement of Androgen Receptor Binding Inhibitory Activity 1 nM [ 3 H] DHT (100 Ci / mmol) and 40
Add 4 nl of a mixed solution of 0 nM-DHT, the receptor solution according to the above item (1) and a specimen sample of various concentrations (total volume 250 μl).
After incubating at 16 ° C. for 16 hours, 5% (w / v) activated carbon and 0.5% (w / v) dextran (molecular weight 6
250 μl of a solution containing 0000 to 90,000) was added and centrifuged at 4 ° C. for 10 minutes to obtain a supernatant. This supernatant 2
After taking 00 μl and mixing with liquid scintillation cocktail, the specific binding amount of [ 3 H] DHT to the receptor was measured using a liquid scintillation counter.
Find the inhibition rate more.
【0026】[0026]
【数1】 B CONT:検体試料を添加しない場合の受容体と[3H]
DHTの特異的結合量 B SAMPLE:検体試料を添加した場合の受容体と[3H]
DHTの特異的結合量 結果を表1に示す。[Equation 1] B CONT: Receptor and [ 3 H] when sample is not added
Specific binding amount of DHT B SAMPLE: Receptor and [ 3 H] when sample is added
Table 1 shows the results of the specific binding amount of DHT.
【0027】[0027]
【表1】表1:アンドロゲン受容体結合阻害活性 検 体 試 料 濃度(μm/ml) 阻害率(%) ウスベニアオイ抽出エキス 100 53.1 ヤクモソウ抽出エキス 500 26.6 ゴボウシ抽出エキス 100 33.8 キンセンカ抽出エキス 500 26.3 クサノオウ抽出エキス 500 16.8 サイカチ抽出エキス 500 19.8 サンシシ抽出エキス 500 20.2 キンモクセイ抽出エキス 500 13.8 [Table 1] Table 1: Androgen Receptor Binding Inhibitory Activity Test Sample Concentration (μm / ml) Inhibition Rate (%) Scutellaria baicalensis Extract Extract 100 53.1 Yakusoma Extract Extract 500 26.6 Burdock Extract Extract 100 33.8 Calendula Extract 500 26.3 Kusanou Extract Extract 500 16.8 Ringworm extract Extract 500 19.8 Sanshishi extract Extract 500 20.2 Ginkgo biloba extract 500 13.8
【0028】実施例2 各乾燥生薬細断物10gに各々10倍量(w/v)の3
0%(v/v)エタノール水溶液を加え50℃の水浴中
で2時間抽出した。次にろ過し、エタノールを除去した
後凍結乾燥して下記の通りそれぞれ抽出エキスを得た。Example 2 10 g of each dried herb shredded product was mixed with 10 times amount (w / v) of 3 each.
A 0% (v / v) ethanol aqueous solution was added, and the mixture was extracted for 2 hours in a water bath at 50 ° C. Then, the mixture was filtered, ethanol was removed, and then freeze-dried to obtain the extract as follows.
【0029】 Cedronエキス 1.082g Hierba Luisaエキス 1.564g Achicoriaエキス 2.001g Maticoエキス 1.836g Cardo Santoエキス 2.755g Ortiga negraエキス 1.969g Chancapiedraエキス 1.020g Munaエキス 1.576g Asnac−ccoraエキス 1.416g Choloqueエキス 0.864g Una de gatoエキス 1.777g Kiwichaエキス 2.560g Algarroboエキス 1.598g Manzanillaエキス 1.620gCedron Extract 1.082g Hierba Luisa Extract 1.564g Achicoria Extract 2.001g Matico Extract 1.836g Cardo Santo Extract 2.755g Ortiga Negra Extract 1.969g Chancapiedra Extract 1.020g Muna Extract 1.4576g Ucora Extract. gato extract 1.777g Kiwicha extract 2.560g Algarrobo extract 1.598g Manzanilla extract 1.620g
【0030】試験例2:5α−リダクターゼ活性阻害効
果 (1) 5α−リダクターゼ溶液の調製 頸椎脱臼により屠殺したwistar系雄性ラット(1
2週令)の前立腺を摘出し、50mMトリス塩酸緩衝液
(pH7.4)、1.5mMエチレンジアミン四酢酸、
1mMジチオスレイトール、10mMモリブデン酸ナト
リウムおよび10%(w/v)グリセロールを含有する
5倍量(w/v)の溶液でホモジナイズした後、700
×g、4℃で10分間遠心して得られた上清を酵素液と
した。Test Example 2: 5α-reductase activity inhibitory effect (1) Preparation of 5α-reductase solution Wistar male rats sacrificed by cervical dislocation (1
2 weeks old) prostate is removed, 50 mM Tris-HCl buffer (pH 7.4), 1.5 mM ethylenediaminetetraacetic acid,
After homogenization with a 5 volume (w / v) solution containing 1 mM dithiothreitol, 10 mM sodium molybdate and 10% (w / v) glycerol, 700
The supernatant obtained by centrifuging for 10 minutes at 4 ° C. was used as an enzyme solution.
【0031】(2) 5α−リダクターゼ阻害活性の測
定 [3H]テストステロン(2μCi)10μl、3.3
mM NADPH(ニコチンアミドアデニンジヌクレオ
チドリン酸・還元型)溶液150μl、種々の濃度の検
体試料100μlと(1)項で得た酵素液250μlを
加え37℃で振とうした。ついでクロロホルム/メタノ
ール(2/1)混液2mlを加えて反応を止め、700
℃×gで10分間遠心して抽出液を分離した。この抽出
液を薄層クロマトスキャナーにてテストステロンおよび
その代謝物(DHT、アンドロスタンジオール)のピー
ク面積を測定し、次式数2より阻害率を求める。(2) Measurement of 5α-reductase inhibitory activity [ 3 H] testosterone (2 μCi) 10 μl, 3.3
150 μl of mM NADPH (nicotinamide adenine dinucleotide phosphate / reduced type) solution, 100 μl of specimen samples of various concentrations and 250 μl of the enzyme solution obtained in (1) were added and shaken at 37 ° C. Then, 2 ml of a mixed solution of chloroform / methanol (2/1) was added to stop the reaction, and 700
The extract was separated by centrifuging at ℃ × g for 10 minutes. The peak area of testosterone and its metabolites (DHT, androstanediol) of this extract is measured with a thin-layer chromatographic scanner, and the inhibition rate is calculated from the following equation 2.
【0032】[0032]
【数2】 結果を表2に示す。[Equation 2] The results are shown in Table 2.
【0033】[0033]
【表2】表2:5α−リダクターゼ活性阻害効果 検 体 試 料 濃度(%) 阻害率(%) セドロンエキス 0.1 44.0 イエルバ・ルイサエキス 0.1 38.0 アチコリアエキス 0.1 19.3 マチコエキス 0.1 58.5 カルド・サントエキス 0.1 3.5 オルティガ・ネグラエキス 0.1 43.6 チャンカピエドラエキス 0.1 15.6 ムナエキス 0.1 19.0 アズナック−コラエキス 0.1 31.3 コロケエキス 0.1 9.5 ウナ・デ・ガトエキス 0.1 44.0 キウィチャエキス 0.1 4.8 アルガロボエキス 0.1 5.4 マンザニラエキス 0.1 43.3 [Table 2] Table 2: 5α-reductase activity inhibitory test substance Concentration (%) Inhibition rate (%) Cedron extract 0.1 44.0 Yerba Luisa extract 0.1 38.0 Atticoria extract 0.1 19.3 Machico extract 0.1 58.5 Cardo Santo extract 0.1 3.5 Ortiga・ Negra Extract 0.1 43.6 Chanka Piedra Extract 0.1 15.6 Muna Extract 0.1 19.0 Aznak-Kola Extract 0.1 31.3 Coloke Extract 0.1 9.5 Una de Gato Extract 0.1 44.0 Kiwicha Extract 0.1 4.8 Arugalobo Extract 0.1 5.4 Manzanilla Extract 0.1 43.3
【0034】試験例3 試験例1と同様にしてアンドロゲン受容体結合阻害活性
を測定し、結果を表3に示した。Test Example 3 The androgen receptor binding inhibitory activity was measured in the same manner as in Test Example 1, and the results are shown in Table 3.
【0035】[0035]
【表3】表3:アンドロゲン受容体結合阻害効果 検 体 試 料 濃度(μm/ml) 阻害率(%) セドロンエキス 500 25.2 イエルバ・ルイサエキス 500 26.9 アチコリアエキス 500 16.2 マチコエキス 500 60.3 カルド・サントエキス 500 13.4 オルティガ・ネグラエキス 500 13.0 チャンカピエドラエキス 500 22.0 ムナエキス 500 23.1 アズナック−コラエキス 500 19.8 コロケエキス 500 25.6 ウナ・デ・ガトエキス 500 15.2 キウィチャエキス 500 14.3 アルガロボエキス 500 27.6 マンザニラエキス 100 17.5 [Table 3] Table 3: Androgen receptor binding inhibitory effect Test substance concentration (μm / ml) Inhibition rate (%) Cedron extract 500 25.2 Yerba Luisa extract 500 26.9 Aticoria extract 500 16.2 Machico extract 500 60.3 Cardo Santo extract 500 13.4 Ortiga Negra Extract 500 13.0 Chanka Piedra Extract 500 22.0 Muna Extract 500 23.1 Aznak-Kola Extract 500 19.8 Coloke Extract 500 25.6 Una De Gato Extract 500 15.2 Kiwicha Extract 500 14.3 Arugalobo Extract 500 27.6 Manzanilla Extract 100 17.5
【0036】皮脂分泌抑制効果に優れた化粧料を、以下
の処方で調製した。なお、%はすべて重量基準である。A cosmetic having an excellent effect of suppressing sebum secretion was prepared by the following formulation. All percentages are by weight.
【0037】実施例3 化粧水 グリセリンモノステアレート 1.0% イソプロピルパルミテート 3.0% ラノリン 1.0% グリセリン 5.0% パラオキシ安息香酸メチルエステル 0.1% ステアリルコラミノホルミルメチルピリジウムクロライド 1.5% セドロンエキス 0.1% イエルバ・ルイサエキス 0.2% アチコリアエキス 0.2% 香料、色素 微量 水 残 計 100.0% Example 3 Toner lotion Glycerin monostearate 1.0% Isopropyl palmitate 3.0% Lanolin 1.0% Glycerin 5.0% Paraoxybenzoic acid methyl ester 0.1% Stearyl colaminoformylmethylpyridinium chloride 1.5% Cedron extract 0.1% Yerba luisa extract 0.2% Achikoria extract 0.2% Fragrance, pigment Trace water remaining 100.0%
【0038】実施例4 乳液 グリセリルエーテル 1.5% ポリオキシエチレン(20)硬化ヒマシ油 1.5% モノステアリン酸ソルビタン 1.0% スクワラン 10.0% ジプロピレングリコール 5.0% マチコエキス 0.1% カルド・サントエキス 0.2% オルティガ・ネグラエキス 0.2% 香料 微量 水 残 計 100.0% Example 4 Emulsion Glyceryl ether 1.5% Polyoxyethylene (20) hydrogenated castor oil 1.5% Sorbitan monostearate 1.0% Squalane 10.0% Dipropylene glycol 5.0% Machiko extract 0.1% Cardo Santo extract 0.2% Ortiga negra extract 0.2 % Fragrance, trace amount of water 100.0%
【0039】実施例5 軟膏 固体パラフィン 10.0% 蜂ろう 10.0% スクワラン 10.0% サリチル酸 0.3% 亜鉛華 0.5% チャンカピエドラエキス 0.1% ムナエキス 0.2% アズナック−コラエキス 0.2% 香料 微量 ワセリン 残 計 100.0%Example 5 Ointment Solid paraffin 10.0% Beeswax 10.0% Squalane 10.0% Salicylic acid 0.3% Zinc white 0.5% Chanka piedra extract 0.1% Muna extract 0.2% Aznak-cola extract 0.2% Fragrance Trace petrolatum Residual 100.0%
【0040】実施例6 ヘアトニック エタノール 59.0% グリセリン 5.0% サリチル酸 0.3% ジステアリルジメチルアンモニウムクロライド 1.0% コロケエキス 0.2% ウナ・デ・ガトエキス 0.2% キウィチャエキス 0.2% 香料 0.5% 水 残 計 100.0%Example 6 Hair Tonic Ethanol 59.0% Glycerin 5.0% Salicylic acid 0.3% Distearyldimethylammonium chloride 1.0% Coloke extract 0.2% Una de gato extract 0.2% Kiwicha extract 0.2% Fragrance 0.5% Water balance 100.0%
【0041】実施例7 ヘアリンス ステアリルジメチルベンジルアンモニウムクロライド 2.0% ポリオキシエチレンセチルエーテル 1.2% ポリオキシエチレンラノリンエーテル 3.0% プロピレングリコール 5.0% クエン酸 0.1% クエン酸ナトリウム 0.1% パラオキシ安息香酸ブチル 0.05% パラオキシ安息香酸メチル 0.1% アルガロボエキス 0.2% マンザニラエキス 0.2% 香料 0.2% 水 残 計 100.0%Example 7 Hair rinse Stearyl dimethylbenzyl ammonium chloride 2.0% Polyoxyethylene cetyl ether 1.2% Polyoxyethylene lanolin ether 3.0% Propylene glycol 5.0% Citric acid 0.1% Sodium citrate 0.1% Butyl paraoxybenzoate 0.05% Paraoxybenzoic acid Methyl 0.1% Arugalobo extract 0.2% Manzanilla extract 0.2% Fragrance 0.2% Water balance 100.0%
【0042】実施例8 ヘアシャンプー ラウリル硫酸トリエタノールアミン 15.0% ラウリル硫酸モノエタノールアミド 5.0% ステアリン酸マグネシウム 1.5% 液状ラノリン 1.0% モノステアリン酸プロピレングリコール 1.25% セドロンエキス 0.3% マチコエキス 0.2% ムナエキス 0.1% 香料、色素 0.2% 水 残 計 100.0%Example 8 Hair Shampoo Lauryl Sulfate Triethanolamine 15.0% Lauryl Sulfate Monoethanolamide 5.0% Magnesium Stearate 1.5% Liquid Lanolin 1.0% Propylene Glycol Monostearate 1.25% Cedron Extract 0.3% Machico Extract 0.2% Muna Extract 0.1% Fragrance, Dye 0.2% Water balance 100.0%
【0043】実施例9 制汗剤 アルミニウムクロロヒドロオキシド 20.0% プロピレングリコール 5.0% エタノール 10.0% 殺菌剤 0.2% アチコリアエキス 0.2% マチコエキス 0.2% コロケエキス 0.2% 香料 0.2% 水 残 計 100.0%Example 9 Antiperspirant Aluminum chlorohydroxide 20.0% Propylene glycol 5.0% Ethanol 10.0% Bactericide 0.2% Athikoria extract 0.2% Machiko extract 0.2% Coloke extract 0.2% Perfume 0.2% Water balance 100.0%
Claims (1)
シ、キンセンカ、クサノオウ、サイカチ、サンシシ、キ
ンモクセイ、セドロン、イエルバ・ルイサ、アチコリ
ア、マチコ、カルド・サント、オルティガ・ネグラ、チ
ャンカピエドラ、ムナ、アズナック−コラ、コロケ、ウ
ナ・デ・ガト、キウィチャ、アルガロボおよびマンザニ
ラから選ばれる少なくとも一種の植物の抽出エキスを有
効成分として含有することを特徴とする抗男性ホルモン
剤。Claims: 1. Alveolus, Yakusou, Burdock, Calendula, Limbo, Ginkgo, Sanshishi, Ginkgo sardines, Cedron, Yerba Luisa, Athikoria, Machiko, Cardo Santo, Ortiga Negra, Chankapiedra, Muna, Aznak-Kora, Koroke, Koroke, Koroke. An anti-androgen agent comprising, as an active ingredient, an extract of at least one plant selected from Una de Gato, Kiwicha, Argarovo and Manzanilla.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25856991A JP3177642B2 (en) | 1991-09-10 | 1991-09-10 | Antiandrogens |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25856991A JP3177642B2 (en) | 1991-09-10 | 1991-09-10 | Antiandrogens |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0570360A true JPH0570360A (en) | 1993-03-23 |
JP3177642B2 JP3177642B2 (en) | 2001-06-18 |
Family
ID=17322066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP25856991A Expired - Fee Related JP3177642B2 (en) | 1991-09-10 | 1991-09-10 | Antiandrogens |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3177642B2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07138135A (en) * | 1993-11-17 | 1995-05-30 | Mikimoto Pharmaceut Co Ltd | 5alpha-reductase inhibitor |
JP2001220320A (en) * | 2000-02-09 | 2001-08-14 | Mandom Corp | Hair-growing agent composition |
WO2001059448A1 (en) * | 2000-02-10 | 2001-08-16 | Chugai Seiyaku Kabushiki Kaisha | Method of screening antiandrogen agent |
JP2001226231A (en) * | 2000-02-18 | 2001-08-21 | Mandom Corp | Hair grower composition |
DE10223486A1 (en) * | 2002-05-27 | 2003-12-11 | Beiersdorf Ag | Cosmetic and / or dermatological preparation with 2,3-dibenzylbutyrolactones |
JP2005126366A (en) * | 2003-10-23 | 2005-05-19 | Nippon Menaade Keshohin Kk | TESTOSTERONE-5alpha-REDUCTASE INHIBITOR |
KR100521783B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
JP2006096750A (en) * | 2004-09-03 | 2006-04-13 | Taizo Ayukawa | Stock solution for hair growth inhibitor, hair growth inhibitor, method for producing the same and method for hair growth inhibition |
JP2007008965A (en) * | 2006-10-23 | 2007-01-18 | Pola Chem Ind Inc | Hair growing agent |
FR2890310A1 (en) * | 2005-09-06 | 2007-03-09 | Sederma Soc Par Actions Simpli | USE OF PROTOBERBERINS AS AGENTS REGULATING THE ACTIVITY OF THE PILOSEBACEE UNIT |
JP2007514705A (en) * | 2003-12-18 | 2007-06-07 | アノキシマー ゲーエムベーハー | Use of extracts of aloysia / verbena / lippia trifira / citriodra for the treatment of chronic and / or inflammatory diseases |
JP2008511613A (en) * | 2004-09-01 | 2008-04-17 | ルピン・リミテッド | Purified arabinogalactan-protein (AGP) composition |
JP2014505725A (en) * | 2011-05-10 | 2014-03-06 | ユタカ 宮内 | Prostate cancer drug |
CN104147139A (en) * | 2013-05-08 | 2014-11-19 | 浙江大学 | Application of sweet-scented osmanthus polyphenol extract |
JP2016135758A (en) * | 2015-01-14 | 2016-07-28 | 御木本製薬株式会社 | Hyaluronic acid synthesis promoting agent |
WO2018016455A1 (en) * | 2016-07-19 | 2018-01-25 | 株式会社山田養蜂場本社 | Nourishing tonic |
CN112076238A (en) * | 2019-06-12 | 2020-12-15 | 康品科技有限公司 | Application of burdock extract |
-
1991
- 1991-09-10 JP JP25856991A patent/JP3177642B2/en not_active Expired - Fee Related
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07138135A (en) * | 1993-11-17 | 1995-05-30 | Mikimoto Pharmaceut Co Ltd | 5alpha-reductase inhibitor |
JP2001220320A (en) * | 2000-02-09 | 2001-08-14 | Mandom Corp | Hair-growing agent composition |
WO2001059448A1 (en) * | 2000-02-10 | 2001-08-16 | Chugai Seiyaku Kabushiki Kaisha | Method of screening antiandrogen agent |
JP2001226231A (en) * | 2000-02-18 | 2001-08-21 | Mandom Corp | Hair grower composition |
DE10223486A1 (en) * | 2002-05-27 | 2003-12-11 | Beiersdorf Ag | Cosmetic and / or dermatological preparation with 2,3-dibenzylbutyrolactones |
KR100521783B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
JP2005126366A (en) * | 2003-10-23 | 2005-05-19 | Nippon Menaade Keshohin Kk | TESTOSTERONE-5alpha-REDUCTASE INHIBITOR |
JP2007514705A (en) * | 2003-12-18 | 2007-06-07 | アノキシマー ゲーエムベーハー | Use of extracts of aloysia / verbena / lippia trifira / citriodra for the treatment of chronic and / or inflammatory diseases |
JP2008511613A (en) * | 2004-09-01 | 2008-04-17 | ルピン・リミテッド | Purified arabinogalactan-protein (AGP) composition |
JP2006096750A (en) * | 2004-09-03 | 2006-04-13 | Taizo Ayukawa | Stock solution for hair growth inhibitor, hair growth inhibitor, method for producing the same and method for hair growth inhibition |
FR2890310A1 (en) * | 2005-09-06 | 2007-03-09 | Sederma Soc Par Actions Simpli | USE OF PROTOBERBERINS AS AGENTS REGULATING THE ACTIVITY OF THE PILOSEBACEE UNIT |
WO2007029187A3 (en) * | 2005-09-06 | 2007-10-11 | Sederma Sa | Use of protoberberines as an active substance regulating the pilosebaceous unit |
JP2009507012A (en) * | 2005-09-06 | 2009-02-19 | セデルマ | Use of protoberberine as an active substance that regulates the activity of the pilosebaceous unit |
JP2007008965A (en) * | 2006-10-23 | 2007-01-18 | Pola Chem Ind Inc | Hair growing agent |
JP2014505725A (en) * | 2011-05-10 | 2014-03-06 | ユタカ 宮内 | Prostate cancer drug |
CN104147139A (en) * | 2013-05-08 | 2014-11-19 | 浙江大学 | Application of sweet-scented osmanthus polyphenol extract |
JP2016135758A (en) * | 2015-01-14 | 2016-07-28 | 御木本製薬株式会社 | Hyaluronic acid synthesis promoting agent |
WO2018016455A1 (en) * | 2016-07-19 | 2018-01-25 | 株式会社山田養蜂場本社 | Nourishing tonic |
JPWO2018016455A1 (en) * | 2016-07-19 | 2019-05-09 | 株式会社山田養蜂場本社 | Nourishing tonic |
CN112076238A (en) * | 2019-06-12 | 2020-12-15 | 康品科技有限公司 | Application of burdock extract |
JP2020200325A (en) * | 2019-06-12 | 2020-12-17 | 康品科技有限公司 | Use of burdock extract |
US11207364B2 (en) * | 2019-06-12 | 2021-12-28 | Kang Pin Technology Co., Ltd. | Method for treating benign prostatic hyperplasia (BPH) |
Also Published As
Publication number | Publication date |
---|---|
JP3177642B2 (en) | 2001-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0570360A (en) | Androgenic hormone-resistant agent | |
JP2001354579A (en) | Anti-inflammatory cosmetic | |
JPH0248515A (en) | Hair tonic | |
JP4672124B2 (en) | Testosterone 5α-reductase inhibitor and androgen receptor binding inhibitor, anti-androgen hormone agent, hair nourishing cosmetic, prostate hypertrophy inhibitor and health supplement | |
JP4033981B2 (en) | Testosterone 5α-reductase inhibitor | |
JPH08310923A (en) | Testosterone 5alpha-reductase inhibitor | |
JP2003221315A (en) | Skin care preparation for external use to be used for hair growth | |
JP5191525B2 (en) | Testosterone 5α-reductase inhibitor and androgen receptor binding inhibitor, anti-androgen hormone agent, hair nourishing cosmetic, and prostate hypertrophy inhibitor | |
JP3165832B2 (en) | Antiandrogens | |
JP2001187742A (en) | Testosteron-5-alfa-reductase inhibitor | |
JP2011219462A (en) | Cosmetic or phamaceutical composition containing kuzu flower extract | |
JP3050667B2 (en) | Antiandrogens | |
JP2002241296A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR, ANDROGEN RECEPTOR BINDING INHIBITOR, ANTIANDROGENIC AGENT, HAIR COSMETIC, PROSTATOMEGALY INHIBITOR AND HEALTH SUPPLEMENT | |
JP4975225B2 (en) | Hair restorer | |
JP2002308790A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR, ANDROGEN RECEPTOR- BINDING INHIBITOR, ANTIANGROGENIC AGENT, AND HAIR GROWTH COSMETIC | |
JPH09227341A (en) | Anti-androgenic agent | |
JP2005145902A (en) | TESTOSTERONE-5alpha-REDUCTASE INHIBITOR | |
JPH06128170A (en) | Anti-male hormone agent | |
JP2003055162A5 (en) | ||
JPH06128169A (en) | Anti-male hormone agent | |
JP2008189558A (en) | Testosterone 5α-reductase inhibitor | |
JPH11310518A (en) | Hair restorer | |
JP2007099698A (en) | Skin cosmetic and hair care cosmetic | |
JPH1179948A (en) | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion | |
JPH10139680A (en) | Antiandrogen agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080413 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090413 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090413 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100413 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110413 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |